Investors

Paradigm reports on Phase 2b OA/BMEL Clinical Trial (18 December 2018)

Paradigm Biopharmaceuticals Ltd is pleased to announce that it has met its primary endpoint of its phase 2b randomised double-blind placebo-controlled multi-centre clinical trial.

Please see our ASX announcements and the video below for more information.

Board

View our Board

READ MORE

ASX Announcements

All the latest data and announcements from the Australian Stock Exchange

READ MORE

Corporate governance

View and download our Corporate Governance statements.

READ MORE

IP / patents & trademarks

Intellectual property is an important part of Paradigm’s ownership of the repurposing programs that we run. We protect these programs through trade secrets, partnerships, patents and trade marks.

READ MORE

Presentations

View and download our latest presentations.

READ MORE

Adopting an intelligent and agile approach to clinical research and development, our experienced team are passionate in our commitment to the quality of our programmes.

Annual reports

View our and download our Annual Reports.

READ MORE

Media & Analyst reports

View the latest media and analyst reports.

READ MORE

Peer-reviewed publications

Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report.

READ MORE

Information sheets

View and download our information sheets.

READ MORE

Current share price

View our current share price.

READ MORE

A key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.